KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.80

Model-Informed Drug Development of Subcutaneous Nivolumab: Comparison of Pharmacokinetic Analysis Methodologies Using Clinical Trial Simulation.

Yue Zhao, Heather Vezina, Zheyi Hu, Anna Kondic, Li Zhu, Amit Roy

CPT Pharmacometrics Syst Pharmacol 14(12) 2107-2117

PMID40990036
PMCIDPMC12706396
DOI10.1002/psp4.70120
发表日期2025-09-24
入排依据:The record describes a Phase III randomized controlled trial in oncology (CheckMate 67T) but focuses solely on pharmacokinetic analysis and model-informed drug development, not on reporting survival, progression, recurrence, death, or related efficacy outcomes for KM digitization.
已检查 5 张 PMC Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 other;FIGURE 5:AI 判定为 other。
摘要

摘要

A subcutaneous formulation of nivolumab was evaluated in the phase III study CheckMate 67T (NCT04810078). The co-primary pharmacokinetic exposure endpoints, time-averaged serum concentration over the first 28 days (Cavgd28), and steady-state trough concentration (Cminss) were determined through population pharmacokinetic analysis as compared to conventional non-compartmental analysis (NCA). We proposed a model-based approach to determine subcutaneous and intravenous nivolumab exposures in CheckMate 67T, leveraging extensive prior pharmacokinetic data across various tumor types. The robustness of this model-informed drug development (MIDD) approach was assessed via clinical trial simulations. Concentration-time profiles in randomly sampled patients with renal cell carcinoma receiving second-line systemic therapy were simulated for subcutaneous/intravenous nivolumab. Population pharmacokinetic parameters, sampled from the joint parameter uncertainty distribution, were applied in simulations based on the CheckMate 67T design. Two population pharmacokinetic approaches-the PRIOR subroutine ($PRIOR) in NONMEM and a pooled analysis with historical nivolumab pharmacokinetic data-were used to analyze the simulated data. Results were compared to NCA using intensive and conventional sampling schemes. Analyses showed that model-based analysis provided more accurate area under the curve estimates than NCA. Model-predicted exposure measures, including Cavgd28, maximum serum concentration after the first dose, and minimum serum concentration at day 28, were also consistent across both population pharmacokinetic approaches, with minimal differences in geometric means. In conclusion, both the $PRIOR and pooled population pharmacokinetic methods yielded more accurate results compared to conventional NCA. The MIDD approach was validated as a robust and feasible method to support non-inferiority assessment based on clinical trial simulations.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1General workflow. i.v., intravenous; NCA, non‐compartmental analysis; PK, pharmacokinetic; pop, population; s.c., subcutaneous.
非 KM Figure
FIGURE 2Median (90% PI) of simulated geometric mean concentration–time profile by route of administration. Solid line and the shaded area represent the median (90% PI) of the geometric mean across the 88 simulations (87 from parameters simulated with uncertainty and one simulation using point of estimate of the parameter). Dashed line indicates simulated geometric mean of C maxss for patients with RCC after nivolumab i.v. administration of 10 mg/kg q2w (352 μg/mL), a dosing regimen that has been shown to be safe and tolerable. i.v., intravenous; PI, prediction interval; s.c., subcutaneous.
非 KM Figure
FIGURE 3Distribution of nivolumab exposures ( C avgd28 , C max1 , C mind28 ) by administration route and analysis method (without uncertainty). $PRIOR, PRIOR subroutine in NONMEM; C avgd28 , time‐averaged serum concentration over the first 28 days; C max1 , peak concentration after the first dose; C mind28 , minimum concentration at day 28; CV, coefficient of variation; GM, geometric mean; i.v., intravenous; NCA, non‐compartmental analysis; NCA‐24, NCA with one sample every 24 h; s.c., subcutaneous.
非 KM Figure
FIGURE 4Distribution of estimated geometric mean nivolumab exposures ( C avgd28 , C max1 , C mind28 ) by administration route and analysis method (with uncertainty). $PRIOR, PRIOR subroutine in NONMEM; C avgd28 , time‐averaged serum concentration over the first 28 days; C max1 , peak concentration after the first dose; C mind28 , minimum concentration at day 28; CV, coefficient of variation; i.v., intravenous; NCA, non‐compartmental analysis; NCA‐12, NCA with one sample every 12 h; NCA‐24, NCA with one sample every 24 h; NCA‐C, NCA‐conventional; s.c., subcutaneous.
非 KM Figure
FIGURE 5Comparison of simulated geometric mean ratios (s.c./i.v.) of nivolumab ( C avgd28 , C max1 , C mind28 , C minss ) by popPK analysis approach and NCA (with uncertainty). $PRIOR, PRIOR subroutine in NONMEM; C avgd28 , time‐averaged serum concentration over the first 28 days; C max1 , peak concentration after the first dose; C mind28 , minimum concentration at day 28; C minss , minimum concentration at steady state; CV, coefficient of variation; GMR, geometric mean ratio; i.v., intravenous; NCA, non‐compartmental analysis; NCA‐12, NCA with one sample every 12 h; NCA‐24, NCA with one sample every 24 h; NCA‐C, NCA‐conventional; popPK, population pharmacokinetics; s.c., subcutaneous.
非 KM Figure